Literature DB >> 18534386

Comparison of the Insall-Burstein II and NexGen legacy total knee arthroplasty systems with respect to patella complications.

Christopher H Kavolus1, Matthew T Hummel, Kathryn P Barnett, James E Jennings.   

Abstract

This study retrospectively contrasts 2 cohorts of consecutive patients ""(N = 202) after primary total knee arthroplasty with respect to the types and numbers of patella and extensor mechanism complications. Our results demonstrated an overall decrease of patellofemoral complications associated with the NexGen Legacy PS system (Zimmer Inc, Warsaw, Ind). Patella fractures decreased from 6 to 0 (P = .013), avascular necrosis from 9 to 0 (P = .0002), and lateral retinacular release trended down from 24 to 14. The Insall-Burstein II (Zimmer Inc, Warsaw, Ind) has a significantly higher incidence of patella fractures, avascular necrosis, and the lateral retinacular release. We feel that the alteration and adjustment of the patellofemoral dimension in the NexGen Legacy design to a more anatomical, extended design of the femoral component and patella modifications led to a decrease in the incidence of complications.

Entities:  

Mesh:

Year:  2007        PMID: 18534386     DOI: 10.1016/j.arth.2007.07.016

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  2 in total

1.  Cruciate-retaining TKA using a third-generation system with a four-pegged tibial component: a minimum 10-year followup note.

Authors:  Adam J Schwartz; Craig J Della Valle; Aaron G Rosenberg; Joshua J Jacobs; Richard A Berger; Jorge O Galante
Journal:  Clin Orthop Relat Res       Date:  2010-05-04       Impact factor: 4.176

2.  Improving radiographic patello-femoral tracking in total knee arthroplasty with the use of a flexion spacer: a case-control study.

Authors:  Davide Giuseppe D'Elicio; Marco Attanasio; Gaetano Ruffo; Stefan Mogos; Nicola Ursino; Riccardo D'Ambrosi; Franco Parente
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2020-04-11       Impact factor: 4.342

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.